[Recent progress in development of hypnotic drugs].
The patient of insomnia in the advanced countries come up to 25 approximately 33% in populations. The pharmaco-therapy, especially hypnotic drug is useful treatment in insomnia. I reviewed the developing hypnotic drugs in Japan. One benzodiazepine and 2 non-benzodiazepines. These hypnotics have selective affinity to benzodiazepine receptor omega 1 subtype. The half-life-time of the developing benzodiazepine hypnotic drug is long, therefore the rebound insomnia can not be recognized. Those of non-benzodiazepine hypnotics are short, namely 1-3 hours. The former drug has finished the clinical studies and waiting the permission for marketing from the government. The latter have still been under the clinical studies. We can expect these hypnotics will bring a certain advantages for our insomnia treatment in future.
Yamadera
H
H
Department of Neuropsychiatry, Nippon Medical School.
D000081:Acetamides; D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007858:Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects; D011247:Pregnancy; D011725:Pyridines; D011743:Pyrimidines; D012893:Sleep Wake Disorders / Q000188:drug therapy; D000077334:Zolpidem
D000081:Acetamides; D014151:Anti-Anxiety Agents; D006993:Hypnotics and Sedatives; D011725:Pyridines; D011743:Pyrimidines; D001569:Benzodiazepines; D000077334:Zolpidem; C025130:quazepam; C085665:zaleplon